(ANSA) – ROME, 19 SEPTEMBER – The Phase III Cabinet study evaluated the cabozantinib molecule compared to placebo in patients with advanced pancreatic neuroendocrine tumors (pNETs) or advanced extrahepatic neuroendocrine tumors (epNETs) that had progressed after prior systemic therapy. The data show a statistically significant reduction in the risk of disease progression or death with cabozantinib compared to placebo of 77% and 62% in patients with advanced pNETs and epNETs, respectively. The data were presented at the 2024 Congress of the European Society for Medical Oncology (Esmo 2024) and published in the New England Journal of Medicine.
“Patients with neuroendocrine tumors face many challenges, from ensuring an early diagnosis to having optimal treatment options that meet the needs of the growing number of people with this tumor,” said Teodora Kolarova, Executive Director, International Neuroendocrine Cancer Alliance. “These latest data confirm the possibility of continued scientific progress in neuroendocrine tumors, offering the potential for new therapies that can significantly impact the daily lives of these patients who face a complex diagnosis.”
The number of newly diagnosed neuroendocrine tumors (NETs) is estimated to be increasing due to increased knowledge and improved diagnostic methods, with approximately 35 in 100,000 patients currently affected by NETs globally. However, despite improved understanding of the disease, the nonspecific nature of symptoms of this type of tumor often leads patients to see multiple specialists and undergo multiple types of tests before reaching an accurate diagnosis. As a result, approximately one-third of people take at least five years to be diagnosed with NETs, contributing to poor patient outcomes. Most NETs are indolent in nature and can develop anywhere in the body, requiring multiple lines of therapy as the disease progresses.
Treatment options at the time of disease progression are often limited and depend on the primary site of the tumor, causing difficulty in identifying the optimal treatment path specific to the patient’s condition. (ANSA).
2024-09-19 19:22:17